Hagen Heidi 4

What Happened
Heidi Hagen, a director of Vericel Corporation (VCEL), reported multiple derivative-related transactions on April 29, 2026. The Form 4 shows two exercise/conversion entries of 3,200 shares each and two grant/award entries of 8,000 and 3,200 shares, all recorded as acquired with $0 consideration. The combined transactions on that date total 17,600 shares tied to option/derivative activity and RSU awards; no open‑market purchases or sales were reported.

Key Details

• Transaction date: April 29, 2026; Form 4 filed May 1, 2026 (appears timely).
• Reported entries: M (exercise/conversion) — 3,200 shares and 3,200 shares; A (award/grant) — 8,000 shares and 3,200 shares. All reported as $0 consideration.
• Shares owned after transaction: Not specified in the provided filing.
• Notable footnotes:
  • F1–F3/F6 indicate RSUs (each representing a right to one share) and vesting schedules: some RSUs vested as a result of prior grants (vesting tied to April 30, 2026 or annual meeting timing) while other RSUs have later vesting (e.g., April 29, 2027 or related annual meeting).
  • F5 notes an option vests over a 1‑year period in equal monthly increments (service‑based).
  • F4 notes no expiration date for that award type.
• No 10b5-1 plan, tax‑withholding sale, or cashless sale is indicated; no shares were reported sold.

Context
These entries are derivative settlements and RSU grants/vests rather than open‑market buys or sales. $0 consideration typically reflects vested awards converting into common stock (or settlement of equity awards) rather than a cash purchase; such transactions are common compensation events for insiders and do not by themselves indicate buying or selling sentiment.